The immune system must strike a delicate balance between defending the host against pathogens and maintaining tolerance to self. Dendritic cells (DCs), as professional antigen-presenting cells, are pivotal in orchestrating this balance. Among them, tolerogenic DCs (tolDCs) have emerged as promising candidates for restoring immune tolerance in autoimmune diseases and supporting graft acceptance in transplantation. Unlike general immunosuppressants, tolDCs enable antigen-specific immune modulation, offering precision without global immunosuppression. This thesis investigates how oxygen (O₂)-dependent metabolic programming influences DC biology, with the aim of optimizing tolDC generation for therapeutic use. The central hypothesis posits that O₂ tension—a key physiological cue—can direct DC metabolism and thus influence their immunological identity. The project was motivated by a practical bottleneck: lower differentiation efficiency of GMP-grade tolDCs compared to conventional DCs (cDCs), possibly linked to altered metabolic demands. Preliminary data indicated higher O₂ consumption in tolDCs, prompting an in-depth investigation into the effects of physiological O2 levels (physioxia; 4% O₂), which better reflects in vivo tissue conditions than standard atmospheric O₂ (21%). A literature review highlights that most in vitro DC studies rely on non-physiological oxygen levels, potentially skewing results. Low O₂ tension is shown to modulate DC metabolism, phenotype, cytokine profiles, and T cell interactions, advocating for the adoption of physioxic culture conditions. Experimental work demonstrated that cDCs cultured under physioxia acquired a more tolerogenic profile with reduced T cell stimulatory capacity, without compromising mitochondrial integrity. In contrast, tolDCs generated under physioxia maintained key tolerogenic features and displayed a glycolytic metabolic shift, supporting their robustness across O₂ conditions and affirming the robustness of current GMP protocols. To streamline tolDC assessment, the release of apoptotic bodies (ApoBDs) was evaluated as a surrogate marker of tolerogenic potential. TolDCs released significantly more ApoBDs than cDCs in responsive donor cultures, although correlations with functional potency did not reach significance. Nonetheless, ApoBDs remain a promising candidate for early-phase product screening. Together, these findings highlight the critical role of microenvironmental O₂ tension in modulating DC fate and function. They also offer practical insights into optimizing tolDC manufacturing and quality control, paving the way toward more effective, antigen-specific immunotherapies.